Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies
Metrics: PDF 624 views | HTML 833 views | ?
Nikita Pozdeyev1, Minjae Yoo1, Ryan Mackie1, Rebecca E. Schweppe1, Aik Choon Tan1,*, Bryan R. Haugen1,*
1Department of Medicine, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, CO, USA
*Two senior authors contributed equally to this work
Nikita Pozdeyev, email: email@example.com
Keywords: database integration, drug sensitivity, pharmacogenomics, cancer, cell line
Received: April 08, 2016 Accepted: May 29, 2016 Published: June 14, 2016
The consistency of in vitro drug sensitivity data is of key importance for cancer pharmacogenomics. Previous attempts to correlate drug sensitivities from the large pharmacogenomics databases, such as the Cancer Cell Line Encyclopedia (CCLE) and the Genomics of Drug Sensitivity in Cancer (GDSC), have produced discordant results. We developed a new drug sensitivity metric, the area under the dose response curve adjusted for the range of tested drug concentrations, which allows integration of heterogeneous drug sensitivity data from the CCLE, the GDSC, and the Cancer Therapeutics Response Portal (CTRP). We show that there is moderate to good agreement of drug sensitivity data for many targeted therapies, particularly kinase inhibitors. The results of this largest cancer cell line drug sensitivity data analysis to date are accessible through the online portal, which serves as a platform for high power pharmacogenomics analysis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.